Dipeptidyl peptidase-4 inhibitor treatment could decrease Klebsiella pneumoniae pneumonia in patients with type 2
Hsin-Hung Chen1,2, Ching-Chu Chen3,4, Chun-Wei Ho1
1Intelligent Diabetes Metabolism and Exercise Center, China Medical University Hospital , Taichung, Taiwan.
Postgraduate Medicine
|July 8, 2020
Summary
Dipeptidyl peptidase-4 inhibitors (DPP4i) significantly reduced the risk of Klebsiella pneumoniae (KP) pneumonia in patients with type 2 diabetes. This suggests DPP4i may offer a protective effect against this common infection in diabetic populations.
Area of Science:
- Infectious Diseases
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes is associated with an increased risk of infections.
- Klebsiella pneumoniae (KP) pneumonia is a serious concern in diabetic patients.
- Dipeptidyl peptidase-4 inhibitors (DPP4i) are commonly used to manage type 2 diabetes.
Purpose of the Study:
- To investigate the potential protective effect of DPP4 inhibitors against Klebsiella pneumoniae pneumonia in individuals with type 2 diabetes.
- To analyze the association between DPP4 inhibitor use and the incidence of KP pneumonia.
Main Methods:
- Population-based, observational study involving patients newly diagnosed with type 2 diabetes (2009-2012).
- Utilized multivariable Cox proportional hazards models and propensity score adjustments to assess KP pneumonia risk.
- Employed Kaplan-Meier method and log-rank test to compare cumulative incidence between DPP4i users and non-users.
Main Results:
- DPP4 inhibitor users exhibited a lower incidence rate of KP pneumonia (1.51 per 1000 person-years) compared to non-users (2.25 per 1000 person-years).
- DPP4 inhibitor use was associated with a significantly lower cumulative incidence of KP pneumonia (p=0.03).
- Adjusted hazard ratio indicated a 33% lower risk of KP pneumonia in DPP4 inhibitor users (aHR=0.67, 95% CI=0.48-0.95).
Conclusions:
- DPP4 inhibitor use is associated with a decreased risk of Klebsiella pneumoniae pneumonia in patients with type 2 diabetes.
- Factors such as male gender, comorbidities, higher Diabetes Complications Severity Index (DCSI) score, and higher defined daily dose (DDD) of DPP4i were linked to reduced KP pneumonia risk.
- The potential role of DPP4 inhibitors in modulating immunological responses warrants further consideration.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
457
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
457
01:24Glucagon-like Receptor Agonists
713
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
713
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
513
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
513
01:28Pneumonia IV: Management
651
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
651
01:06Oral Hypoglycemic Agents: Glinides
482
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
482
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
197
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
197